IO Biotech stock price target lowered to $4 at Morgan Stanley

Morgan Stanley has lowered its price target for IO Biotech (NASDAQ:IOBT) to $4.00 from $6.00, while maintaining an Overweight rating, following a narrow miss on the primary endpoint of its Phase 3 Cylembio trial for advanced melanoma, despite strong progression-free survival trends. The firm reduced Cylembio's probability of success to 40% but awaits FDA feedback as IO Biotech plans to file for regulatory approval by late 2025. Currently trading at $1.05, IOBT also recently regained Nasdaq compliance, underscoring a high-stakes clinical outlook dependent on regulatory clarity.

Analysis

Morgan Stanley has revised its outlook on IO Biotech (IOBT), reducing the price target to $4.00 from $6.00 while maintaining an Overweight rating. This decision is a direct consequence of the company's pivotal Phase 3 trial for its cancer vaccine, Cylembio, which narrowly missed statistical significance on its primary endpoint. Despite this setback, the trial data revealed a strong signal in progression-free survival, with the Cylembio combination therapy showing a median of 19.4 months compared to 11.0 months for the control arm. Reflecting the increased clinical uncertainty, Morgan Stanley has lowered its estimated probability of success for Cylembio to 40% from 50%. The company's future is now heavily dependent on upcoming discussions with the FDA, as IO Biotech still intends to pursue regulatory approval by the end of 2025. Concurrently, the company has resolved a near-term risk by regaining compliance with Nasdaq's minimum bid price requirement, although its current share price of $1.05 remains significantly below all analyst targets.

Key Decisions for Investors

• Investors should view IO Biotech as a high-risk, event-driven special situation, with the stock's performance almost entirely contingent on the outcome of its future engagement with the FDA regarding the Cylembio data.
• Consider the asymmetric risk-reward profile; while the clinical miss creates substantial downside, the maintained Overweight rating and $4.00 price target from Morgan Stanley suggest significant potential upside if a regulatory path forward is established.
• Monitor for any announcements related to FDA feedback and the planned regulatory filing timeline, as this will be the primary catalyst determining the viability of the current investment thesis.